secwatch.observer — SEC 8-K summary
======================================

Issuer:     BECTON DICKINSON & CO (BDX)
CIK:        0000010795
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001628280-26-031638
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BD Q2 FY2026 revenue $4.7B (+5.2% reported), GAAP EPS $(0.13), adj. EPS $2.90; raises FY adj. EPS guidance
--------------------------------------------------------------------------------

- Revenue $4,714M, +5.2% reported/2.6% FX-neutral; GAAP diluted EPS $(0.13) from continuing ops vs $0.55 prior year.
- Adjusted diluted EPS $2.90, up from $2.79 (+3.9% reported); company raises full-year adjusted EPS guidance.
- Executed $2.0B accelerated share repurchase and retired $2.1B of debt in the quarter.
- Reaffirms revenue growth guidance; more than 90% of business delivered mid-single-digit growth.
- Spin-off of Biosciences & Diagnostic Solutions completed Feb 9, 2026; results reflect continuing ops.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10795/000162828026031638/0001628280-26-031638-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10795/000162828026031638/bdx-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-031638

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer